List of Figures
Figure 1: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Alzheimer’s Disease, 2016–2023
Figure 2: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Parkinson’s Disease, 2016–2023
Figure 3: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Multiple Sclerosis, 2016–2023
Figure 4: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Huntington’s Disease, 2016–2023
Figure 5: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Amyotrophic Lateral Sclerosis, 2016–2023
Figure 6: Neurodegenerative Disease Drugs Market, Global, Multiple Sclerosis Disease Profiling, 2017
Figure 7: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Key Players, 2006–2023
Figure 8: Neurodegenerative Disease Drugs Market, Global, Market Share of Copaxone, Tecfidera, Gilenya, Avonex, Tysabri and Ocrevus Within MS, 2006–2023
Figure 9: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Copaxone ($bn), 2006–2023
Figure 10: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Tecfidera, 2013–2023
Figure 11: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Gilenya, 2011–2023
Figure 12: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Avonex, 2006–2023
Figure 13: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Tysabri, 2006–2023
Figure 14: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Ocrevus, 2017–2023
Figure 15: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Namenda/ Ebixa/ Axura/ Abixa/ Memary, 2006–2023
Figure 16: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Aricept, 2006–2023
Figure 17: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Azilect, 2006–2023
Figure 18: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Neupro, 2006–2023
Figure 19: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Radicut, 2006–2023
Figure 20: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Xenazine, 2006–2023
Figure 21: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Spinraza ($bn), 2016–2023
Figure 22: Neurodegenerative Disease Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
Figure 23: Neurodegenerative Disease Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2018
Figure 24: Neurodegenerative Disease Drugs Market, Global, Pipeline by Key Indications and Stage of Development, 2018
Figure 25: Neurodegenerative Disease Drugs Market, Global, Pipeline by Key Indications and Molecule Type, 2018
Figure 26: Neurodegenerative Disease Drugs Market, Global, Pipeline by Stage of Development and Molecular Target, 2018
Figure 27: Neurodegenerative Disease Drugs Market, Global, Pipeline by Molecular Target, 2018
Figure 28: Neurodegenerative Disease Drugs Market, Global, Pipeline by Key Indications and Molecular Target, 2018
Figure 29: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2018
Figure 30: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2018
Figure 31: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2018
Figure 32: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2018
Figure 33: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018
Figure 34: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2018
Figure 35: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2018
Figure 36: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2018
Figure 37: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development, 2006–2018
Figure 38: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication, 2006–2017
Figure 39: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type, 2006–2018
Figure 40: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target, 2006–2018
Figure 41: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development, 2006–2018
Figure 42: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development and Indication, 2006–2018
Figure 43: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type, 2006–2018
Figure 44: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target, 2006–2017
Figure 45: Neurodegenerative Disease Drugs Market, Global, Revenue for Aducanumab ($bn), 2020–2023
Figure 46: Neurodegenerative Disease Drugs Market, Global, Revenue for Azeliragon ($bn), 2019–2023
Figure 47: Neurodegenerative Disease Drugs Market, Global, Revenue for ChariSMA ($bn), 2019–2023
Figure 48: Neurodegenerative Disease Drugs Market, Global, Revenue for Omaveloxolone ($bn), 2019–2023
Figure 49: Neurodegenerative Disease Drugs Market, Global, Revenue for Siponimod ($bn), 2019–2023
Figure 50: Neurodegenerative Disease Drugs Market, Global, Revenue for Ozanimod ($bn), 2018–2023
Figure 51: Neurodegenerative Disease Drugs Market, Global, Revenue for Elenbecestat ($m), 2020–2023
Figure 52: Neurodegenerative Disease Drugs Market, Global, Revenue for BAN-2401 ($m), 2020–2023
Figure 53: Neurodegenerative Disease Drugs Market, Global, Revenue for IONIS-HTTRx ($m), 2020–2023
Figure 54: Neurodegenerative Disease Drugs Market, Global, Market Size ($bn), 2016–2023
Figure 55: Neurodegenerative Disease Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2016–2023
Figure 56: Neurodegenerative Disease Drugs Market, Global, Key Products Market Share, 2016–2023
Figure 57: Neurodegenerative Disease Drugs Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016–2023
Figure 58: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Neuromodulators ($bn), 2016–2023
Figure 59: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Immunomodulators ($bn), 2016–2023
Figure 60: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Stress-related inhibitors ($bn), 2016–2023
Figure 61: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Protein Misfolding and Aggregation Inhibitors ($bn), 2016–2023
Figure 62: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Neuroprotectants ($bn), 2016–2023
Figure 63: Neurodegenerative Disease Drugs Market, Global, Company Analysis Matrix, 2016–2023
Figure 64: Neurodegenerative Disease Drugs Market, Global, Cluster Graph by Growth and Market Share, 2016–2023
Figure 65: Neurodegenerative Disease Drugs Market, Global, Forecast Revenue by Company, 2016–2023
Figure 66: Neurodegenerative Disease Drugs Market, Global, Forecast Market Share by Company (%), 2016-2023
Figure 67: Neurodegenerative Disease Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
Figure 68: Neurodegenerative Disease Drugs Market, Global, Revenue by Product Type, 2016-2023
Figure 69: Neurodegenerative Disease Drugs Market, Global, Biogen Annual Revenue Forecast ($bn), 2016-2023
Figure 70: Neurodegenerative Disease Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2016-2023
Figure 71: Neurodegenerative Disease Drugs Market, Global, Novartis AG Annual Revenue Forecast ($bn), 2016-2023
Figure 72: Neurodegenerative Disease Drugs Market, Global, Teva Annual Revenue Forecast ($bn), 2016-2023
Figure 73: Neurodegenerative Disease Drugs Market, Global, Eisai Annual Revenue Forecast ($bn), 2016-2023
Figure 74: Neurodegenerative Disease Drugs Market, Global, Sanofi Annual Revenue Forecast ($bn), 2016-2023
Figure 75: Neurodegenerative Disease Drugs Market, Global, Companies by Type, 2018
Figure 76: Neurodegenerative Disease Drugs Market, Global, High-Activity and Late-Stage Developers by Level of Neurodegenerative Specialization, 2018
Figure 77: Neurodegenerative Disease Drugs Market, Global, Proportion of Total Company Revenue Attributed to Neurodegenerative Disorders, 2016–2023
Figure 78: Neurodegenerative Disease Drugs Market, Global, Licensing Deals by Region, Year and Value, 2006-2018
Figure 79: Neurodegenerative Disease Drugs Market, Global, Licensing Deal Volume and Value by Indication, 2006–2018
Figure 80: Neurodegenerative Disease Drugs Market, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2018
Figure 81: Neurodegenerative Disease Drugs Market, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006-2018
Figure 82: Neurodegenerative Disease, Global, Licensing Deals with Disclosed Deal Values, 2006–2018
Figure 83: Neurodegenerative Disease, Global, Licensing Deals with Disclosed Deal Values, 2006–2018
Figure 84: Neurodegenerative Disease, Global, Licensing Deals with Disclosed Deal Values, 2006–2018
Figure 85: Neurodegenerative Disease Drugs Market, Global, Co-development Deals by Region Value and Year, 2006–2018
Figure 86: Neurodegenerative Disease Drugs Market, Global, Co-development Deal Volume and Value by Indication, 2006–2018
Figure 87: Neurodegenerative Disease Drugs Market, Global, Co-development Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2018
Figure 88: Neurodegenerative Disease Drugs Market, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006–2018
Figure 89: Neurodegenerative Disease Drugs Market, Global, Co-development Deals with Disclosed Deal Values, 2006–2018
Figure 90: Neurodegenerative Disease Drugs Market, Global, Co-development Deals with Disclosed Deal Values, 2006–2018
Figure 91: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Discovery, 2018
Figure 92: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Discovery, 2018
Figure 93: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Discovery, 2018
Figure 94: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Discovery, 2018
Figure 95: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Discovery, 2018
Figure 96: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 97: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 98: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 99: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 100: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 101: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 102: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 103: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 104: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 105: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 106: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 107: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 108: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 109: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 110: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
Figure 111: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, IND/CTA-filed, 2018
Figure 112: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Phase I, 2018
Figure 113: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Phase I, 2018
Figure 114: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Phase I, 2018
Figure 115: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Phase II, 2018
Figure 116: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Phase II, 2018
Figure 117: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Phase II, 2018
Figure 118: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Phase III, 2018
Figure 119: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Pre-registration, 2018